Company
Headquarters: Nedlands, WA, Australia
CEO: Mr. Matthew Liddelow B.Sc.
A$5.8 Million
AUD as of Jan. 1, 2024
US$3.9 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
NeuroScientific Biopharmaceuticals Limited develops diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Cottesloe, Australia.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
NeuroScientific Biopharmaceuticals Limited has the following listings and related stock indices.
Stock: ASX: NSB wb_incandescent